Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Analysis of exposure margins in developmental toxicity studies for detection of human teratogens.

Andrews PA, Blanset D, Costa PL, Green M, Green ML, Jacobs A, Kadaba R, Lebron JA, Mattson B, McNerney ME, Minck D, Oliveira LC, Theunissen PT, DeGeorge JJ.

Regul Toxicol Pharmacol. 2019 Jul;105:62-68. doi: 10.1016/j.yrtph.2019.04.005. Epub 2019 Apr 11.

PMID:
30981719
2.

Applying a weight of evidence approach to the evaluation of developmental toxicity of biopharmaceuticals.

Rocca M, Morford LL, Blanset DL, Halpern WG, Cavagnaro J, Bowman CJ.

Regul Toxicol Pharmacol. 2018 Oct;98:69-79. doi: 10.1016/j.yrtph.2018.07.006. Epub 2018 Jul 24. Review.

PMID:
30009863
3.

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.

Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, Rattel B, Adam PJ, Anderson KC, Friedrich M.

Leukemia. 2017 Oct;31(10):2278. doi: 10.1038/leu.2017.219. Epub 2017 Jul 28.

PMID:
28751764
4.

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.

Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, Rattel B, Adam PJ, Anderson KC, Friedrich M.

Leukemia. 2017 Aug;31(8):1743-1751. doi: 10.1038/leu.2016.388. Epub 2016 Dec 27. Erratum in: Leukemia. 2017 Jul 28;:.

PMID:
28025583
5.

Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.

Selby MJ, Engelhardt JJ, Johnston RJ, Lu LS, Han M, Thudium K, Yao D, Quigley M, Valle J, Wang C, Chen B, Cardarelli PM, Blanset D, Korman AJ.

PLoS One. 2016 Nov 18;11(11):e0167251. doi: 10.1371/journal.pone.0167251. eCollection 2016.

6.

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.

Selby MJ, Engelhardt JJ, Johnston RJ, Lu LS, Han M, Thudium K, Yao D, Quigley M, Valle J, Wang C, Chen B, Cardarelli PM, Blanset D, Korman AJ.

PLoS One. 2016 Sep 9;11(9):e0161779. doi: 10.1371/journal.pone.0161779. eCollection 2016. Erratum in: PLoS One. 2016 Nov 18;11(11):e0167251.

7.

In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.

Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, Singh S, Wong S, Garner N, Leblanc H, Bunch RT, Blanset D, Selby MJ, Korman AJ.

Cancer Immunol Res. 2014 Sep;2(9):846-56. doi: 10.1158/2326-6066.CIR-14-0040. Epub 2014 May 28.

8.

Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.

Roberts SA, Andrews PA, Blanset D, Flagella KM, Gorovits B, Lynch CM, Martin PL, Kramer-Stickland K, Thibault S, Warner G.

Regul Toxicol Pharmacol. 2013 Dec;67(3):382-91. doi: 10.1016/j.yrtph.2013.08.017. Epub 2013 Sep 5.

PMID:
24012707
9.

Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial.

Horvath C, Andrews L, Baumann A, Black L, Blanset D, Cavagnaro J, Hastings KL, Hutto DL, MacLachlan TK, Milton M, Reynolds T, Roberts S, Rogge M, Sims J, Treacy G, Warner G, Green JD.

Nat Rev Immunol. 2012 Oct;12(10):740; author reply 740. doi: 10.1038/nri3192-c1. Epub 2012 Aug 31. No abstract available. Erratum in: Nat Rev Immunol. 2012 Oct;12(10):740.

PMID:
22941443
10.

Phase I study evaluating the safety and pharmacokinetics of MDX-1303, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers.

Riddle V, Leese P, Blanset D, Adamcio M, Meldorf M, Lowy I.

Clin Vaccine Immunol. 2011 Dec;18(12):2136-42. doi: 10.1128/CVI.05059-11. Epub 2011 Oct 5.

11.

Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices.

Morford LL, Bowman CJ, Blanset DL, B√łgh IB, Chellman GJ, Halpern WG, Weinbauer GF, Coogan TP.

Birth Defects Res B Dev Reprod Toxicol. 2011 Aug;92(4):359-80. doi: 10.1002/bdrb.20305. Epub 2011 Jul 18. Review.

PMID:
21770023
12.

Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: history, experience, methodology, and future directions.

Leach MW, Halpern WG, Johnson CW, Rojko JL, MacLachlan TK, Chan CM, Galbreath EJ, Ndifor AM, Blanset DL, Polack E, Cavagnaro JA.

Toxicol Pathol. 2010 Dec;38(7):1138-66. doi: 10.1177/0192623310382559. Epub 2010 Oct 6.

PMID:
20926828
13.

A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies.

Cardarelli PM, Rao-Naik C, Chen S, Huang H, Pham A, Moldovan-Loomis MC, Pan C, Preston B, Passmore D, Liu J, Kuhne MR, Witte A, Blanset D, King DJ.

Cancer Immunol Immunother. 2010 Feb;59(2):257-65. doi: 10.1007/s00262-009-0746-z.

PMID:
19657637
14.

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, Keler T, Graziano R, Blanset D, Yellin M, Fischkoff S, Assad A, Borchmann P.

J Clin Oncol. 2007 Jul 1;25(19):2764-9. Epub 2007 May 21.

PMID:
17515574
15.

Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity.

Vitale L, Blanset D, Lowy I, O'Neill T, Goldstein J, Little SF, Andrews GP, Dorough G, Taylor RK, Keler T.

Infect Immun. 2006 Oct;74(10):5840-7.

16.

CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques.

Hryniewicz A, Boasso A, Edghill-Smith Y, Vaccari M, Fuchs D, Venzon D, Nacsa J, Betts MR, Tsai WP, Heraud JM, Beer B, Blanset D, Chougnet C, Lowy I, Shearer GM, Franchini G.

Blood. 2006 Dec 1;108(12):3834-42. Epub 2006 Aug 8. Erratum in: Blood. 2009 Oct 1;114(14):3132.

17.

Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques.

Keler T, Halk E, Vitale L, O'Neill T, Blanset D, Lee S, Srinivasan M, Graziano RF, Davis T, Lonberg N, Korman A.

J Immunol. 2003 Dec 1;171(11):6251-9.

18.

Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation.

Lane WJ, Hattori K, Dias S, Peerschke EI, Moore MA, Blanset DL, Lang PC, Petrone M, Rafii S.

Exp Hematol. 2001 Dec;29(12):1417-24.

PMID:
11750100

Supplemental Content

Loading ...
Support Center